ERBB2 and breast carcinoma: Here, using CRISPR/Cas9 technology, we interfered with expression of the PRLR in two different breast cancer cell model systems representative of the two luminal/epithelial breast cancer subtypes HR+ (MCF-7 cells) and HER2-E (SKBR-3 cells).